We demonstrated that CaMKII contributes to hyperglycemia-induced RF/6A cells apoptosis by activating both Fas-dependent and mitochondrial apoptosis pathways, suggesting that CaMKII is an important therapeutic target for DR. This evidence concerns the gene FAS and Hyperglycemia.